Overall survival (os) of patients (pts) with relapsed and refractory multiple myeloma (rrmm): Adjusting for crossover in the mm-003 trial for pomalidomide plus low-dose dexamethasone (pom + lodex) vs. High-dose dexamethasone (hidex)

Authors:

Morgan G, San Miguel J, Dhanasiri S, Lee D, Palumbo A, Facon T, Zaki M, Yu X, Sternas L, Jacques C, Weisel K, Offner F and Dimopoulos M.

Publication Type:

Conference Proceedings – Poster

Publication Name:

19th Congress of European Hematology Association

Citation:

Morgan G, San Miguel J, Dhanasiri S, Lee D, Palumbo A, Facon T, Zaki M, Yu X, Sternas L, Jacques C, Weisel K, Offner F and Dimopoulos M. Overall survival (os) of patients (pts) with relapsed and refractory multiple myeloma (rrmm): Adjusting for crossover in the mm-003 trial for pomalidomide plus low-dose dexamethasone (pom + lodex) vs. High-dose dexamethasone (hidex) 19th Congress of European Hematology Association. Milan, Italy. 12-15 June 2014. Poster.


Link to publication ⟶

⟵ Back to Search Results

By continuing to browse or by clicking "Accept All Cookies" you agree to the storing of first and third-party cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookie Policy
Accept All Cookies
By continuing to browse or by clicking "Accept All Cookies" you agree to the storing of first and third-party cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookie Policy
Accept All Cookies